M. Erkan ÖZCAN
(İnönü Üniversitesi, Tıp Fakültesi, Psikiyatri Anabilim Dalı, Malatya, Türkiye)
Louise R. LEVINE
(Girilmedi)
William Z. POTTER
(Girilmedi)
Yıl: 2000Cilt: 10Sayı: 1ISSN: 1017-7833 / 1302-9657Sayfa Aralığı: 38 - 42İngilizce

43 3
Panic provocation studies with placebo
Amaç: Bu makalede, panik bozukluğu olan hastalarla ya da sağlıklı bireylerle, plasebo kontrollü olarak yapılmış olan panik provokasyonu çalışmaları gözden geçirilmiştir. Yöntem: İngilizce yazılmış dergiler ve medline taranarak konu ile ilgili makalelere ulaşılmış ve bu çalışmalarda elde edilen sonuçlar derlenmiştir. Bulgular: Sodyum laktat, kolesistokinin ve karbondioksit panik provokasyonu amacı ile en çok kullanılan maddelerdir. Bu maddelere genel olarak bakıldığında duyarlı, güvenli ve güvenilir görünmektedirler. Sonuçlar: Bu çalışmalarda elde edilen bulgular, panik provokasyon testlerinin, hem halen anksiyete bozukluklarının dışındaki endikasyonlarda kullanılmakta olan ilaçların, hem de yeni bulunacak ilaçların anksiyete bozukluklarındaki etkinliğini ölçebileceğini göstermektedir. Panik provokasyonu çalışmaları, anksiyete bozukluklarının oluş mekanizmalarının daha iyi anlaşılmasına katkıda bulunabilirler.
Fen > Eczacılık > Farmakoloji ve Eczacılık
DergiAraştırma MakalesiErişime Açık
  • 1. van den Hout MA, Griez E. Panic symptoms after inhalation of carbondioxide. Br J Psychiatry 1984;144:503-507.
  • 2. Coryell W, Arndt S. The 35% CO2 inhalation procedure: test-retest reliability. Biol Psychiatry 1999;45:923-927.
  • 3. Price LH, Goddard AW, Barr LC, Goodman WK. Pharmacological Challenges in Anxiety Disorders. In: Psychopharmacology: The Fourth Generation of Progress, edited by Floyd E. Bloom and David J. Kupfer. Raven Press, Ltd., New York, 1995.
  • 4. Gorman JM, Fyer MR, Liebowitz MR, Klein DF. Pharmacologic provocation of panic attacks. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press; 1987;985-993.
  • 5. Gorman JM, Azkanazi J, Liebowitz MR, Fyer AJ, Stein J, Kinney JM, Klein DF. Response to hyperventilation in a group of patients with panic disorder. Am J Psychiatry 1984;141:857-861.
  • 6. Gorman JM, Fyer MR, Goetz R. Ventilatory physiology of patients with panic disorder. Arch Gen Psychiatry 1988; 45:31-39.
  • 7. Griez E, Lousberg H, van den Hout MA, van der Molen GM. CO2 vulnerability in panic disorder. Psychiatry Res 1987;20:87-95.
  • 8. Bertani A, Perna G, Arancio C, Caldirola D, Bellodi L. Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. J Clin Psychopharmacol 1997;17:97-101.
  • 9. De Montigny C. Cholecystokinin tetrapeptide induces panic like attacks in healthy volunteers. Arch Gen Psychiatry 1989;46:511-517.
  • 10. Pitts FM, McClure JN. Lactate metabolism in anxiety neurosis. N Engl J Med 1967;277:1329-1336.
  • 11. Cowley DS, Arana GW. The diagnostic utility of lactate sensitivity in panic disorder. Arch Gen Psychiatry 1990; 47:277-284.
  • 12. Woods SW, Charney DS, Delgado PL, Heninger GR. The effect of long-term imipramine treatment on carbon dioxide- induced anxiety in panic disorder patients. J Clin Psychiatry 1990;51:505-507.
  • 13. Sanderson WC, Wetzler S, Asnis G. Alprazolam blockade of carbon dioxide-provoked panic in patients with panic disorder. Am J Psychiatry 1994;151:1220-1222.
  • 14. Pols H, Verburg K, Hauzer R, Meijer J, Griez E. Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients. Biol Psychiatry 1996;40:913-917.
  • 15. Carr DB, Sheehan DV, Surman OS, Coleman JH, Greenblatt DJ, Heninger GR, Jones KJ, Levine PH, Watkins WD. Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy. Am J Psychiatry 1986;143:483-494.
  • 16. Bradwejn J, Koszycki D, Couetoux du Tertre A, van Megen H, den Boer J, Westenberg H, Annable L. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 1994;51:486-493.
  • 17. Westenberg H, van Megen H, den Boer J. Effects of the cholecystokinin-B antagonist L-365,260 on lactate-induced panic in panic disorder patients. Psychopharmacology Bulletin 1994;30:644.
  • 18. Cowley DS, Bammert-Adams J, Pyke RE, Cook J, Zaccharias P, Wingerson D, Roy-Byrne PP. Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic. Biol Psychiatry 1996;40:550-552.
  • 19. van Megen H, Westenberg H, den Boer J, Slaap B, Scheepmakers A. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology 1997;129:357-364.
  • 20. Nutt DJ, Glue P, Lawson C, Wilson S. Flumazenil provocation of panic attacks. Arch Gen Psychiatry 1990; 47:917-925.
  • 21. Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine`s anxiogenic effects. Biol Psychiatry 1991;30:973-984.
  • 22. Klein DF. False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch Gen Psychiatry 1993;50:306-317.
  • 23. Strohle A, Kellner M, Yassouridis A, Holsboer F, Wiedemann K. Effect of flumazenil in lactate-sensitive patients with panic disorder. Am J Psychiatry 1998;155:610-612.
  • 24. Benkelfat C, Bradwejn J, Meyer E, Ellenbogen M, Milot S, Gjedde A, Evans A. Functional neuroanatomy of CCK-4- induced anxiety in normal healthy volunteers. Am J Psychiatry 1995;152:1180-1184.
  • 25. Abelson J, Nesse R. Cholecystokinin-4 and panic. Arch Gen Psychiatry 1990;47:395.
  • 26. Bradwejn J. CCK agonists and antagonists in clinical studies of panic and anxiety. Clin Neuropharm 1992; 15(Suppl 1):481-482A.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.